Natera sells DNA tests — prenatal screening and cancer-recurrence monitoring (Signatera).
Natera, Inc. (NTRA) is expected to report earnings on Thursday, November 5, 2026, after the close. Estimated release time 16:09 ET. Consensus EPS estimate is $-0.27.
| Report date | Quarter | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|---|
| 2026-08-06 | Jun 2026 qtr | $-0.49 | $-0.47 | +4.8% | $752.75M |
| 2026-05-07 | Mar 2026 qtr | $-0.54 | $-0.56 | -3.3% | $696.64M |
| 2026-02-26 | Dec 2025 qtr | $-0.51 | $0.35 | — | $665.50M |
| 2025-11-06 | Sep 2025 qtr | $-0.39 | $-0.64 | — | $592.18M |
| 2025-08-07 | Jun 2025 qtr | $-0.62 | $-0.74 | — | $546.60M |
| 2025-05-08 | Mar 2025 qtr | $-0.64 | $-0.50 | — | $501.83M |
| 2025-02-27 | Dec 2024 qtr | $-0.38 | $-0.41 | -7.6% | $476.06M |
| 2024-11-12 | Sep 2024 qtr | $-0.57 | $-0.26 | — | $439.76M |
NTRA has beaten consensus EPS in 1 of its last 3 scored quarters.
See NTRA on the live calendar →